Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0FC8O
|
||||
| Former ID |
DIB001493
|
||||
| Drug Name |
DWP-05195
|
||||
| Synonyms |
DWJ-204; DWP-0519
|
||||
| Indication | Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0] | Phase 2 | [1] | ||
| Company |
Daewoong Pharmaceutical Co Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | Vanilloid receptor 1 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | ||||
| Trk receptor signaling mediated by PI3K and PLC-gamma | |||||
| Reactome | TRP channels | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01557010) Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia. U.S. National Institutes of Health. | ||||
| REF 2 | TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 . | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.